Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel F Hayes

Showing results (201-210 of 336) with videos related to

Pageof 34
Sort By:
Pharmacogenomics|July 24, 2020
Genetic variation in Charcot-Marie-Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathyYongzhen Chen, Fang Fang, Kelley M Kidwell, et al.
Breast Cancer Research and Treatment|February 13, 2019
Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletionLandry K Kamdem, Jingyue Xi, Brandi L Clark, et al.
Pharmacogenomics|June 14, 2019
Effects of <i>SLCO1B1</i> polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozoleJacqueline M Dempsey, Kelley M Kidwell, Christina L Gersch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2016
Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast CancerCorey Speers, Shuang G Zhao, Vishal Kothari, et al.
Molecular Oncology|March 30, 2013
Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancerJeffrey B Smerage, G Thomas Budd, Gerald V Doyle, et al.
Breast Cancer Research and Treatment|May 13, 2019
Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapyJennifer Y Sheng, Amanda L Blackford, Aditya Bardia, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 6, 2011
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncologyPhillip G Febbo, Marc Ladanyi, Kenneth D Aldape, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013Lyndsay N Harris, Gloria Broadwater, Maysa Abu-Khalaf, et al.
The New England Journal of Medicine|March 28, 2019
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast CancerRita S Mehta, William E Barlow, Kathy S Albain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2008
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group BMichael P DiGiovanna, David F Stern, Susan Edgerton, et al.
Pageof 34

Showing results (201-210 of 336) with videos related to

Sort By:
Pageof 34
Pharmacogenomics|July 24, 2020
Genetic variation in Charcot-Marie-Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathyYongzhen Chen, Fang Fang, Kelley M Kidwell, et al.
Breast Cancer Research and Treatment|February 13, 2019
Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletionLandry K Kamdem, Jingyue Xi, Brandi L Clark, et al.
Pharmacogenomics|June 14, 2019
Effects of <i>SLCO1B1</i> polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozoleJacqueline M Dempsey, Kelley M Kidwell, Christina L Gersch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2016
Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast CancerCorey Speers, Shuang G Zhao, Vishal Kothari, et al.
Molecular Oncology|March 30, 2013
Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancerJeffrey B Smerage, G Thomas Budd, Gerald V Doyle, et al.
Breast Cancer Research and Treatment|May 13, 2019
Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapyJennifer Y Sheng, Amanda L Blackford, Aditya Bardia, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 6, 2011
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncologyPhillip G Febbo, Marc Ladanyi, Kenneth D Aldape, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013Lyndsay N Harris, Gloria Broadwater, Maysa Abu-Khalaf, et al.
The New England Journal of Medicine|March 28, 2019
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast CancerRita S Mehta, William E Barlow, Kathy S Albain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2008
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group BMichael P DiGiovanna, David F Stern, Susan Edgerton, et al.
Pageof 34